AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27012596
Drug: Rivastigmine Capsule
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rivastigmine Capsule (6 mg Twice Daily)
Trial: 25423958
Drug: Bleeper Sv
RxNorm normalized name: rifamycin SV
DrugBank: Rifamycin (DB11753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bleeper Sv radiation monitor (real-time operator dose reporting through auditory feedback)
Trial: 3825935
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg slow-release IS-5MN
Trial: 28857848
Drug: IV amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV amikacin 20 mg/kg once daily
Trial: 28857848
Drug: Nebulized amikacin
RxNorm normalized name: Amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Nebulized amikacin 400 mg twice daily
Trial: 25880761
Drug: Fresh frozen
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh frozen plasma (FFP) transfusion (12 ml/kg)
Trial: 19100647
Drug: Irinotecan (I)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (I) monotherapy (300mg/m² i.v. on day 1) every 3 weeks
Trial: 19100647
Drug: Irinotecan (I)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Irinotecan (I) monotherapy
Trial: 11765070
Drug: Opioids (morphine)
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioids (morphine)
Trial: 11765070
Drug: Tricyclic antidepressants
RxNorm normalized name: TRICYCLIC ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tricyclic antidepressants (TC)
Trial: 8024947
Drug: Single enantiomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single enantiomer formulation (SEF) of (S)-atenolol, 50 mg
Trial: 8024947
Drug: Racemic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic mixture (Tenormin, TMN) of (R,S)-atenolol, 100 mg
Trial: 8024947
Drug: Single enantiomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single enantiomer formulation (SEF) of (S)-atenolol
Trial: 7082501
Drug: Nitroprusside infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside infusion
Trial: 5823051
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptives with low dose progestogen and high dose oestrogen
Trial: 5823051
Drug: Sequential oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential oral contraceptives
Trial: 5823051
Drug: Progestogenic combined
RxNorm normalized name: vaginal ring with progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestogenic combined preparations
Trial: 5823051
Drug: Oestrogenic sequential
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestrogenic sequential regimens and low-dose progestogen-only regimens
Trial: 26385346
Drug: Intranasal S.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal S. salivarius 24SMB
Trial: 24217026
Drug: Capsule A
RxNorm normalized name: capsule administration aid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule A containing artificial food colorings (AFCs)
Trial: 24217026
Drug: Capsule B
RxNorm normalized name: Emend 80mg Capsule BiPack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule B containing sodium benzoate
Trial: 11016670
Drug: Neomycin sulfate
RxNorm normalized name: Neomycin Sulfate
DrugBank: Neomycin (DB00994)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neomycin sulfate patch tests with various doses and vehicles
Trial: 11016670
Drug: Serial-dose series
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial-dose series for time intervals ranging from 3 to 96 h
Trial: 8104509
Drug: Debrisoquin (peripheral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Debrisoquin (peripheral monoamine oxidase inhibitor)
Trial: 2425168
Drug: Hydralazine (0.05-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydralazine (0.05-0.3 mg/kg, bolus injections)
Trial: 29561783
Drug: MK7 (360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK7 (360 mcg/day)
Trial: 26611780
Drug: Lactobacillus salivarius
RxNorm normalized name: Lactobacillus Salivarius
DrugBank: Lactobacillus salivarius (DB16544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus salivarius PS2 (9 log10 colony‐forming units daily from week 30 of pregnancy until delivery)
Trial: 24533064
Drug: H7N3 live
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N3 live attenuated influenza vaccine
Trial: 1837510
Drug: Half-sized lunch
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-sized lunch with reduced insulin dose
Trial: 7028238
Drug: Placebo or
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or no-drug conditions
Trial: 20568955
Drug: Combined metformin-clomiphene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined metformin-clomiphene citrate (CC)
Trial: 8986681
Drug: Iron pill
RxNorm normalized name: Elmiron Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron pill (placebo, n = 14)
Trial: 20506062
Drug: Topical cream
RxNorm normalized name: Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream formulation of Ruxolitinib
Trial: 18397484
Drug: 8-week pegIFN-alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-week pegIFN-alpha-2a therapy
Trial: 18397484
Drug: 24-week pegIFN-alpha-2a
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-week pegIFN-alpha-2a therapy
Trial: 6180901
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of triprolidine and pseudoephedrine
Trial: 30823945
Drug: Insulin alone
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin alone (Control)
Trial: 25302456
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 1% lignocaine PPNB and placebo suppository
Trial: 14990632
Drug: Gefitinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib 500 mg/d
Trial: 15838439
Drug: 2 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours of daily patching with near activities
Trial: 15838439
Drug: 2 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 hours of daily patching without near activities
Trial: 12904966
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 mg)
Trial: 25702958
Drug: High dairy
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dairy protein (HP-D, >1.2 g of protein/kg body weight/d; ∼27 g/d dairy protein)
Trial: 23688276
Drug: MPI Cephalexin®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPI Cephalexin® tablet
Trial: 22736448
Drug: 38% silver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 38% silver diamine fluoride (SDF) solution, annual application
Trial: 11428472
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg at bedtime, increased to 20 mg if necessary) with behavioral modification
Trial: 11428472
Drug: Behavioral modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral modification alone (calorie control and daily walking for 30 minutes)
Trial: 9876998
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral administration of alpha-lipoic acid
Trial: 9876998
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg oral administration of alpha-lipoic acid
Trial: 9876998
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg intravenous administration of alpha-lipoic acid
Trial: 2786856
Drug: Erdosteine 900
RxNorm normalized name: erdosteine
DrugBank: Erdosteine (DB05057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdosteine 900 mg/day for one month
Trial: 31928551
Drug: Peer‐identified change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peer‐identified change agents (PICAs)
Trial: 31928551
Drug: Management‐selected change
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Management‐selected change agents (MSCAs)
Trial: 26062124
Drug: Tumor-primed NK
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor-primed NK cells (TpNK) infusion
Trial: 7851099
Drug: Community Treatment
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Treatment Teams (CTTs)
Trial: 29703031
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy administered in the region of the parotid glands bilaterally and in the regions of the submandibular and sublingual glands
Trial: 25424454
Drug: 2 h
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 h 75 g OGTT using the IADPSG criteria
Trial: 21593803
Drug: α-lipoic acid
RxNorm normalized name: α-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: α-lipoic acid (ALA) 600 mg intravenously once daily for 2 weeks
Trial: 12505224
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg plus simvastatin (pooled doses)
Trial: 12505224
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg plus simvastatin 10 mg
Trial: 12505224
Drug: Simvastatin 80
RxNorm normalized name: simvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 80 mg alone
Trial: 11760
Drug: Very high
RxNorm normalized name: Very high density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very high dose fluphenazine decanoate (250 mg weekly)
Trial: 21478660
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (closed treatment)
Trial: 18342398
Drug: High-dose Phe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Phe (10 g)
Trial: 18342398
Drug: Low-dose Phe
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose Phe (5 g Phe and 5 g glucose)
Trial: 18342398
Drug: Control (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (10 g glucose)
Trial: 10826458
Drug: Lansoprazole, 30
RxNorm normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, 30 mg once daily
Trial: 11115698
Drug: DNA vaccine
RxNorm normalized name: HTNV DNA vaccine
DrugBank: Hantaan virus DNA vaccine (DB17808)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNA vaccine (1, 2, or 4 microg)
Trial: 30693609
Drug: Magnesium (250
RxNorm normalized name: magnesium gluconate 12.5 mg magnesium (250 mg) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (250 mg) plus Vitamin E (400 IU)
Trial: 12367545
Drug: Swanson silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swanson silicone trapezium implant
Trial: 1661121
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) given as a single predialysis bolus injection
Trial: 6807125
Drug: Doxapram (1‐1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (1‐1.5 mg/kg)
Trial: 28656922
Drug: Casein phosphopeptide‐amorphous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Casein phosphopeptide‐amorphous calcium fluoride phosphate (CPP‐ACFP) applied daily for 4 min for 4 weeks
Trial: 25125441
Drug: Electrical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electrical stimulation combined with repetitive task practice therapy
Trial: 11895217
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg orally 4x/day for 3 days)
Trial: 10090447
Drug: Dorzolamide three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide three times daily for the first ten days and latanoprost once daily for the second ten days (Group 2)
Trial: 25216510
Drug: LX4211 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX4211 75 mg once daily
Trial: 25216510
Drug: LX4211 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX4211 200 mg once daily
Trial: 25216510
Drug: LX4211 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX4211 200 mg twice daily
Trial: 25216510
Drug: LX4211 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LX4211 400 mg once daily
Trial: 9298509
Drug: Nicotine (0.003-0.012
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (0.003-0.012 mg/kg)
Trial: 9298509
Drug: Atropine (0.001-0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atropine (0.001-0.01 mg/kg)
Trial: 19176272
Drug: Goserelin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goserelin and flutamide (STAD) for 3 or 6 months before and during radiation therapy (66 Gy to the prostate and seminal vesicles)
Trial: 19176272
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (XRT) alone
Trial: 15500814
Drug: Cognitive preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive preparation for video feedback
Trial: 2225508
Drug: Prophylactic antibiotics
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibiotics continued for at least 48 hours in patients requiring a tracheotomy
Trial: 25988676
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) long-acting formulation, 300 mg
Trial: 25988676
Drug: Rilpivirine (RPV)
RxNorm normalized name: Rilpivirine
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rilpivirine (RPV) long-acting formulation, 600 mg
Trial: 22067758
Drug: Doxycycline (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (40 mg daily)
Trial: 11683740
Drug: Somatostatin-14 (S-14)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin-14 (S-14) infusion for 7 days
Trial: 9893697
Drug: Hormonotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonotherapy and chemotherapy
Trial: 9893697
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (letrozole, anastrozole)
Trial: 2303582
Drug: ibuprofen 800
RxNorm normalized name: ibuprofen 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ibuprofen 800 mg tablets
Trial: 2303582
Drug: 325 mg
RxNorm normalized name: lysine 325 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 325 mg aspirin tablets
Trial: 2303582
Drug: ibuprofen suspensions
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen suspensions
Trial: 2303582
Drug: ibuprofen tablets
RxNorm normalized name: Ibuprofen Tablets
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: ibuprofen tablets
Trial: 366897
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug treatment (vincristin, 5‐fluoruracil, methotrexate, cyclophosphane, prednisolone)
Trial: 366897
Drug: Combined drug
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined drug treatment plus ovariectomy and continuous administration of prednisolone, testosterone‐propionate or synoestrol
Trial: 25356603
Drug: Nilotinib 300
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 300 mg bid
Trial: 25356603
Drug: Dasatinib 100
RxNorm normalized name: dasatinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dasatinib 100 mg qd
Trial: 23769755
Drug: 4L polyethylene
RxNorm normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4L polyethylene glycol solution
Trial: 18637100
Drug: Topical estriol
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical estriol
Trial: 17924131
Drug: 0.15 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/m3 epsilon-caprolactam vapours
Trial: 17924131
Drug: 0 mg/m3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/m3 epsilon-caprolactam vapours (control)
Trial: 9876789
Drug: Intravenous PCA
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous PCA with pethidine
Trial: 26886884
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy (PT) for urinary incontinence, 12 weekly sessions
Trial: 23094941
Drug: RealFX™ Q‐Plus™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RealFX™ Q‐Plus™ Chews (500 mg quercetin)
Trial: 23094941
Drug: First Strike™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Strike™ Bars (500 mg quercetin)
Trial: 23094941
Drug: Tang(®) suspension
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tang(®) suspension (500 mg quercetin)
Trial: 12485286
Drug: Dorzolamide 2%
RxNorm normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzolamide 2% and timolol 0.5% fixed combination twice daily
Trial: 25766269
Drug: CaCBT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CaCBT plus Treatment As Usual (TAU)
Trial: 15126574
Drug: Pyridostigmine (PD,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (PD, 120 mg per os)
Trial: 15126574
Drug: Pirenzepine (PZ,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (PZ, 100 mg per os)
Trial: 28407162
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac preoperatively
Trial: 18568885
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac
Trial: 26204202
Drug: Doses greater
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses greater than 300 Gy
Trial: 8314468
Drug: Interferon alfa‐2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alfa‐2b (5 million units, three times weekly)
Trial: 22074724
Drug: Intravenous glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glulisine insulin using a paper-based glucose-lowering algorithm followed by once-daily subcutaneous insulin glargine for 30 days
Trial: 11331318
Drug: Intensive combination
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive combination chemotherapy without local radiation therapy
Trial: 36250
Drug: Indoramin (76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (76 mg/day)
Trial: 36250
Drug: Prazosin (8.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (8.2 mg/day)
Trial: 36250
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alpha‐adrenoreceptor blockers with beta‐adrenoreceptor blockade
Trial: 25445632
Drug: L-arginine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine + nitrate (6 g L-arginine and 614 mg nitrate)
Trial: 25445632
Drug: Nitrate alone
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate alone (614 mg nitrate)
Trial: 25445632
Drug: L-arginine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine + nitrate and nitrate alone
Trial: 12910485
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid supplements
Trial: 24763358
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) for 8 weeks
Trial: 24660604
Drug: Reduning injection
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduning injection and Western Medicine (Group C)
Trial: 24660604
Drug: Western Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western Medicine (Group A)
Trial: 19691852
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of intravenous-grade 70% ethanol into each lumen of the catheter once a week
Trial: 2543656
Drug: Combined progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined progestin and estrogen (medroxyprogesterone acetate, 20 mg tid, and Premarin, 1.25 mg bid)